Introduction
''The combinations of bromide with other drugs are of much value in the treatment of epilepsy. In many cases a greater effect is produced by the combination than by other drugs given alone'' (William Gowers, 1881)
The modern treatment of epilepsy began with potassium bromide and this drug is still in use to this day. 1 The next effective agent, phenobarbital, was not synthesised until 1911. So what else was Gowers giving his epilepsy patients together with potassium bromide? The list included digitalis, belladonna, cannabis, opium, borax and many other noxious substances. It is well known that Vincent van Gogh benefited from treatment with potassium bromide. He also took digitalis for a period of time. Indeed, he may have been digitoxic when he painted some of the canvases with bright yellow overtones, since digitalis toxicity traditionally distorts colour vision in this way. It is unlikely, but not impossible, that he was taking both drugs together at some point! So if Gowers had many polytherapy options more than 100 years ago, what choices does the modern neurologist have in his therapeutic arsenal for treating drug-resistant epilepsy? Over the past 20 years, no fewer than 14 antiepileptic drugs (AEDs) have been licensed for use in the common epilepsies and a range of more unusual syndromes (Fig. 1 ). Of these felbamate (blood dyscrasias and hepatotoxicity) and vigabatrin (concentric visual field defects) are rarely prescribed because of their association with serious adverse effects. 2 Eslicarbazepine is available in Europe, but not in the United States. Stiripentol has been licensed for Dravet's syndrome via the European orphan drug system 3 and rufinamide's usage is confined to seizures associated with Lennox-Gastaut syndrome. 4 Nevertheless, the potential choices of AEDs as monotherapy or in combination are so numerous that it is not possible for a doctor and his or her patient to try every permutation in a single lifetime. Adding the newer AEDS to the established drugs brings their total number up to around 20 for use in the common epilepsies. This allows the possibility of nearly 200 duotherapies or more than 1000 combinations of 3 AEDs! Most patients with refractory epilepsy take 2, 3 or even 4 AEDs. How then are we to rationalise their usage to provide the best possibility of an optimal outcome? What evidence is there in support of ''rational polytherapy''? Conventional wisdom suggests that combining AEDs with different mechanisms of action is more likely to produce seizure freedom than prescribing those with The global introduction of 14 new antiepileptic drugs (AEDs) over the past 20 years as adjunctive treatment in refractory epilepsy has triggered an increased interest in optimising combination therapy. With a widening range of available mechanisms of AED action, much activity has been focused on the defining and refining ''rational polytherapy'' with AEDs that have differing pharmacological properties. This paper reviews the available animal and human data exploring this issue. The experimental and clinical evidence in support of ''rational polytherapy'' is sparse, with only the combination of sodium valproate with lamotrigine demonstrating synergism. Robust evidence to guide clinicians on how and when to combine AEDs is lacking and current practice recommendations are largely empirical. Practical guidance for the clinician is summarised and discussed in this review. In particular, care should be taken to avoid excessive drug load, which can be associated with decreased tolerability and, therefore, reduced likelihood of seizure freedom. A palliative strategy should be defined early for the more than 30% of patients with refractory epilepsy. Nevertheless, the availability of an increasing number of pharmacologically distinct AEDs has produced a modest improvement in prognosis with combination therapy, which will encourage the clinician to persevere with continued pharmacological manipulation when other therapeutic options have been tried or are not appropriate.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. similar or overlapping pharmacological properties. It should be remembered too that the spectrum of efficacy for every drug does not always correspond to the license.
Pharmacological targets
To best use the range of available AEDs, the prescriber must possess some understanding of what we know about how these agents act in the brain. The knowledge base regarding their pharmacology is limited but slowly increasing. We can now identify a range of mechanisms that differ sufficiently from each other to provide some discrimination in their usage.
Blockade of voltage-gated sodium channels is the most common mechanism of action among currently available AEDs. 5 The established agents phenytoin and carbamazepine are archetypal sodium channel blockers, 6 ,7 a mechanism they share with the newer drugs lamotrigine, oxcarbazepine, topiramate, felbamate, zonisamide, rufinamide and lacosamide. [8] [9] [10] Sodium valproate and gabapentin may also have inhibitory effects on neuronal sodium channels. 11, 12 Voltage-gated sodium channels exist in one of three basic conformational states; resting, open, and inactivated. During a single round of depolarisation, channels cycle through these states in turn and the neurone is unable to respond to further depolarisations until a sufficient numbers of voltage-gated sodium channels have returned to the resting state. 13 AEDs with sodium channel blocking properties have highest affinity for the channel protein in the inactivated state and binding slows the otherwise rapid recycling process. As a result, these drugs produce a characteristic voltage-and frequency-dependent reduction in channel conductance, resulting in a limitation of repetitive neuronal firing with little effect on the generation of single action potentials.
14 While most sodium channel blocking AEDs interfere with the fast inactivation pathway, lacosamide selectively influences slow inactivation. 15 Recent evidence suggests that this drug can be usefully combined with sodium channel blockers that act on fast inactivation. 16 Voltage-gated calcium channels represent another important target for several AEDs. 17 The efficacy of ethosuximide and zonisamide in generalised absence epilepsy is believed to be mediated by blockade of the low voltage-activated T-type calcium channel in the dendrites of thalamocortical relay neurones. 18, 19 Sodium valproate may have a similar action. 20 Lamotrigine limits neurotransmitter release by blocking both N-and P/Q-types of the high-voltage-activated (HVA) calcium channel 21 and levetiracetam exerts a partial blockade of N-type calcium currents. 22 Phenobarbital, felbamate, and topiramate are also believed to influence HVA calcium channel conductance, although their effects are less well characterised in terms of channel subtypes or interaction with specific protein subunits. 8, 9 Finally, gabapentin and pregabalin also exert their effects via HVA calcium channels.
Uniquely, they bind to an accessory subunit, termed a 2 d-1, which can modulate the function of various native channels. 23 Activation of the ionotropic GABA A receptor resulting in an enhanced response to synaptically released GABA is a major AED mechanism. 24 Phenobarbital and the benzodiazepines share this effect. They bind to distinct sites on the receptor complex and differentially influence the opening of the chloride ion pore. Typical benzodiazepine-sensitive GABA A receptors are composed of two a-subunits (a1, a2, a3 or a5), two b-subunits (b2 or b3), and a g2 subunit, whereas barbiturates are less selective in terms of subunit preference. 25 Barbiturates prolong the duration of chloride channel opening, while benzodiazepines increase the frequency of opening. 26 In addition, phenobarbital is capable of direct activation of the GABA A receptor in the absence of GABA, an effect which is believed to underlie its sedative properties. 27 Stiripentol has been identified as a subunit selective GABA A enhancer with a preference for a3-B3-g2 containing receptors. 28 Felbamate and topiramate also modulate GABA responses at the GABA A receptor. While their subunit specificity remains to be established, their binding sites and effects on channel kinetics are reported to be distinct from one another and from those observed with barbiturates and benzodiazepines. 29, 30 Finally, levetiracetam can indirectly influence GABA A receptor function by reducing the negative allosteric modulation of the receptor complex by bcarbolines and zinc. 31 Vigabatrin and tiagabine exert their actions by selective neurochemical effects at the inhibitory synapse, resulting in altered GABA turnover. 32 Vigabatrin is an irreversible inhibitor of the mitochondrial enzyme GABA-transaminase, which is responsible for the catabolism of GABA, whereas tiagabine prevents the removal of GABA from the synaptic cleft by blockade of GABA transport. 33, 34 These distinct mechanisms result in the global elevation of brain GABA concentrations and the temporarily prolonged presence of neuronally released GABA in the synapse, respectively. Although these drugs target neurones and glial cells, vigabatrin has marginally higher affinity for neuronal GABAtransaminase, whereas tiagabine is slightly more effective in reducing glial GABA uptake. 32 Furthermore, tiagabine is selective for the GAT-1 GABA transporter and its pharmacological effects mirror the regional distribution of this protein with a more pronounced action in hippocampus and neocortex. 35 Other AEDs, including sodium valproate, gabapentin and topiramate have also been reported to influence GABA turnover by increasing neurotransmitter synthesis and/or release. [36] [37] [38] None of the currently available AEDs exerts its effects solely by an action on the glutamate system. Blockade of the NMDA subtype of glutamate receptor is, however, believed to contribute to the pharmacological profile of felbamate. 39 Topiramate is similarly distinguished by an inhibitory action on AMPA and kainate receptors with a higher affinity for the latter. 40 It has also been suggested that zonisamide may inhibit glutamate-mediated excitatory synaptic transmission, although this is likely to reflect an indirect action on glutamate release mediated by pre-synpatic blockade of sodium and calcium channels. 41 Levetiracetam was developed for the treatment of epilepsy with no clear indication of how it worked at the cellular level. The identification of a specific binding site for the drug in mammalian brain with its later classification as synaptic vesicle protein 2A (SV2A) has resulted in claims that levetiracetam represents the first in a new class of AEDs. 42, 43 However, the precise physiological role of SV2A is still unclear and important details of the interaction between drug and protein remain to be defined. Indeed, there is still no convincing evidence to suggest whether the interaction is facilitatory or inhibitory or if it results in altered packaging, trafficking, membrane fusion or recycling of synaptic vesicles within the nerve terminal. 44 There is, however, credible evidence to support selective binding of levetiracetam to SV2A with little or no affinity for other members of the same protein family, and an impressive correlation between SV2A binding affinity and the anticonvulsant efficacy of a series of levetiracetam analogues in audiogenic seizure sensitive mice. 42 The acid-base balance and maintenance of local pH is critical to normal functioning of the nervous system. Various isoenzymes of carbonic anhydrase play an important role in this regard. They are responsible for catalysing the bi-directional conversion of carbon dioxide and water to bicarbonate and hydrogen ions (CO 2 + H 2 O $ HCO 3 À + H + ). The forward reaction is rapid, whereas the rate of the reverse reaction is more modest. As a result, inhibition of carbonic anhydrase influences the latter more significantly, producing a localised acidosis and increased bicarbonate ion concentration. 45 This, in turn, attenuates excitatory neurotransmission by reducing NMDA receptor activity and enhances inhibitory neurotransmission by facilitating the responsiveness of GABA A receptors. 46 Acetazolamide is a classical carbonic anhydrase inhibitor which has been employed as an AED for more than 50 years. 47 Topiramate and zonisamide share this mechanism, but are significantly less potent and have greater selectivity for individual isoenzymes. For instance, topiramate selectively inhibits CA-II and CA-IV. 48 Lacosamide may also inhibit this enzyme. 49 Thus, it is possible that inhibition of carbonic anhydrase might make a modest contribution to the overall efficacy of a range of AEDs.
Experimental data
Animal models of seizures, epilepsy and drug-related neurotoxicity are widely used in the identification of novel AEDs and many of them have been in routine laboratory use for decades. 50 Together, these models offer an opportunity to characterise the efficacy and toxicity of individual drugs and drug combinations in large groups of genetically homogeneous animals. Despite question marks over their relevance to human epilepsy, and of the doses and acute treatment regimens employed in preclinical studies, these models have been instrumental in the identification of almost all current AEDs and, as such, are a valuable surrogate in the search for optimal combination therapy. 51 Those most commonly used in anticonvulsant drug screening in rodents are maximal electroshock (MES), pentylenetetrazol (PTZ) and spikewave and kindling models for efficacy purposes and the rotarod, horizontal screen, and chimney tests for neurotoxicity. 52 Experimental combination studies should incorporate efficacy and toxicity models in which both drugs are at least minimally effective, use drug ratios that reflect those employed clinically, include drug concentration analysis in both plasma and brain to rule out confounding pharmacokinetic interactions, and employ an appropriate method of analysis such as isobolography or comparison of protective indices. 53 Isobolography is preferable as it provides a robust measure of effectiveness and affords a definitive determination of infra-additive (antagonistic), additive, or supra-additive (synergistic) interactions. 54 The ideal AED combination displays pharmacological synergism, whether it is defined as improved efficacy with similar toxicity, similar efficacy with improved toxicity or, ideally, improved efficacy with improved toxicity. Experimental investigation of AED combinations has a long pedigree. 55 Early studies exploring combinations of established drugs, such as phenobarbital, phenytoin, and carbamazepine, were performed without any knowledge of their mechanisms of action. Interestingly, combinations were commonly reported to be superior, in terms of efficacy, toxicity or both, than either constituent drug alone irrespective of the drugs under investigation. 56 However, this was most evident when two drugs with differing mechanisms of action were combined, e.g. phenobarbital with phenytoin. 57 Less successful were combinations of AEDs with similar mechanisms, e.g. phenytoin with carbamazepine. 58 These studies set the benchmark for the concept of rational polypharmacy as it evolved in the 1990s with the advent of modern AEDs, which are invariably introduced as adjunctive therapy for refractory partial epilepsy, and new knowledge surrounding AED pharmacology. 59 Identifying preferred combinations of AEDs, particularly when starting a new drug, might be regarded as advantageous in terms of maximising efficacy and minimising adverse effects. Considerable experimental effort has been expended on studying combinations of modern AEDs with their older counterparts and, more latterly, with each other. 60, 61 Some common themes have emerged from the vast literature, most notably that combining drugs with differing mechanisms of action appears superior to combining those possessing the same or similar cellular effects. 56 This observation is exemplified by the consistent demonstration of synergism between lamotrigine and sodium valproate in multiple efficacy models 62, 63 and the repeated failure to demonstrate synergism between lamotrigine and either carbamazepine or phenytoin. 62, 64 Other combinations appear to produce less consistent results; for example, gabapentin with carbamazepine is synergistic in the MES model but not in the DBA/2 audiogenicseizure susceptible mouse. 65, 66 Overall, the message is relatively clear; reinforcement on a single pharmacological pathway is less effective than a combined effect on two distinct pathways. The most successful two drug combination in laboratory studies appears to be a single mechanism drug combined with an AED known to possess multiple mechanisms of action. 56 Combinations of drugs that selectively target neuronal voltage-gated sodium channels appear to offer only additive improvements in efficacy and often supra-additive enhancement of neurotoxicity. 61 Unfortunately, there are no meta-analyses or systematic reviews of experimental combination studies which would permit an objective assessment of the available data. This is most likely due to variability in experimental methodology and the difficulty in comparing results across multiple studies. Many investigations are also incomplete; neurotoxicity testing is often not reported, which undermines any suggestion of synergism in terms of efficacy. Pharmacokinetic analysis is rarely performed, which is necessary to rule out the potential for altered drug absorption or brain penetration.
Clinical evidence
The situation regarding clinical evidence in support of ''rational polytherapy'' is similarly sparse. [67] [68] [69] There are claims in the literature supporting particular efficacy for combinations including a sodium channel blocker with a GABA-ergic drug 56 or one with multiple mechanisms of action. 70 However, once again the only supportive evidence for synergism is with sodium valproate and lamotrigine. Brodie and colleagues undertook a pragmatic trial during which an attempt was made to substitute lamotrigine as monotherapy in patients suboptimally treated with carbamazepine, phenytoin or sodium valproate. 71 Adjustment was made in the lamotrigine dosing schedules for the pharmacokinetic interactions among these drugs resulting in similar circulating lamotrigine concentrations for all 3 combinations. When patients were established on both drugs, it was noted that the efficacy was substantially higher in the valproate group than in the patients taking lamotrigine with carbamazepine or phenytoin (Fig. 2) . Following up on this observation, Pisani et al. performed a welldesigned crossover study in 20 patients with partial seizures stabilised on combination therapy. 72 Among the 13 who did not respond to the consecutive addition of sodium valproate and lamotrigine, four patients became seizure free and an additional four experienced >50% seizure reduction when both drugs were given in combination despite lower doses and circulating concentrations than occurred during their separate administration.
Other useful combinations suggested in the literature are largely based on anecdotal reports in small groups of patients or studies with modest sample sizes. These include valproate with ethosuximide for absence seizures, 73 phenobarbital with phenytoin for generalised tonic-clonic seizures, 74 carbamazepine with valproate or vigabatrin for partial seizures, 75 vigabatrin with tiagabine for partial seizures 76 and lamotrigine with topiramate for a range of seizure types. 77 Interestingly, in a multicentre double-blind, placebo-controlled, randomized, parallel group trial of rufinamide 1600 mg twice daily in adults and adolescents with refractory partial seizures, there was a 12% reduction in monthly seizure frequency in the 96 patients established on carbamazepine compared with a 29% seizure reduction (p = 0.05) in the 60 patients taking a regimen that did not contain carbamazepine. 78 Arguably, this observation could suggest that carbamazepine and rufinamide have similar effects on voltage-dependent sodium channels. More recently it has been demonstrated in placebo-controlled dose ranging adjunctive trials with lacosamide that response to this drug was less impressive in patients established on traditional sodium blockers than those taking AEDs with different mechanisms of action, although a dose-dependent statistically significant improvement over placebo was demonstrated in both groups. 16 Combining drugs that block voltage-dependent sodium channels is more likely to produce neurotoxic side-effects, such as dizziness, diplopia and ataxia. 71, [79] [80] [81] A similar scenario, particularly related to a greater likelihood of dizziness, has been reported in patients established on traditional sodium channel blockers compared with those taking other AEDs in a pooled analysis of clinical trial data with adjunctive lacosamide. 16 Introducing lamotrigine in patients established on sodium valproate produces a substantially greater risk of allergic rash than occurs in patients starting on the drug as monotherapy. 82 This is presumed to be a consequence of the inhibitory effect of valproate on lamotrigine metabolism resulting in higher concentrations.
Improved outcomes
There is increasing evidence that the prognosis of treated epilepsy has improved over the past decade, although this has not had a major impact in substantially reducing the size of the refractory epilepsy population. [83] [84] [85] This is perhaps not too surprising since the placebo-corrected efficacy of adjunctive treatment with modern AEDs in double-blind randomized trials has been disappointingly small 86 with very few patients becoming seizure-free even for the limited duration of the study. 87 Data from the expanding cohort of adolescents and adults with newly diagnosed epilepsy in Glasgow, Scotland also support the suggestion that the prognosis has marginally improved since the first analysis a decade ago reported a likely bleak outcome following failure of the first drug due to lack of efficacy. 88 With the advent of a range of mechanistically different AEDs, some patients will now respond to their 3rd, 4th or 5th treatment schedules. 89 Overall a higher percentage of this expanding population had attained seizure-freedom by 2008 (n = 1098; 68.4%) than in the initial analysis conducted in 1998 (n = 470; 64%). Of the 70 in this cohort controlled on polypharmacy, 67 (96%) were taking just two AEDs. These data support those of Schiller and Najjar in suggesting that patients need to fail five, six or even seven drug schedules before they can be recognised as having truly refractory epilepsy. 85 This picture appears similar for the common childhood epilepsies.
90,91
Drug usage
The mechanisms of action of the currently marketed drugs are relatively limited since their anti-seizure properties were identified using a similar array of rodent seizure models. 92 They all inhibit the onset and/or spread of abnormal neuronal synchrony either by decreasing excitation and/or increasing inhibition. 8 Given that we know little about the processes in the brain of individual patients that trigger the initiation of a seizure or switch off the abnormal electrical activity, it seems reasonable to combine AEDs that are pharmacologically distinct. 93 . Even though we do not fully understand the mechanistic minutiae of many available drugs, we can make a good start at separating those that work in similar ways from those that act differently. These are simplified and summarised in Table 1 . This forms the template for those AEDs that can reasonably be combined in patients with drug-resistant epilepsy.
AEDs have different spectra of activity with most sodium blockers, except rufinamide and possibly also lamotrigine, having efficacy for partial and tonic-clonic seizures only. It has been suggested for some time that better outcomes can be obtained in patients established on a sodium channel blocker in combination with a drug that possess a different mechanism of action. 94 Regulatory trial data have demonstrated that lacosamide can be usefully combined with traditional sodium blocking agents. 16 Ethosuximide use is largely confined to absence seizures, whereas gabapentin and pregabalin are used for partial seizures with or without secondary generalisation. 95 As we do not understand how seizures are generated and propagated in the brains of individual patients, adding molecules that possess multiple mechanisms of action, such as valproic acid, levetiracetam, topiramate and zonisamide, may be more likely to provide a beneficial pharmacological effect in the setting of refractory epilepsy. 56, 70 These agents also tend to be broad spectrum across a range of seizure types. Interestingly, the barbiturates and benzodiazepines, which act on the GABA A receptor, also have a broader range of efficacy than other GABA-ergic drugs, such as vigabatrin and tiagabine, that have a selective effect on GABA turnover. In addition there are a handful of AEDs in the pipeline with novel mechanisms of action that should offer opportunities for new and pharmacologically distinct combinations. 96 In particular ezogabine/retigabine (potassium channel opener) and perampanel (selective (AMPA/kainate antagonist) may be useful additions to the therapeutic armamentarium for drug-resistant epilepsy. If a patient tolerates the first, second or third monotherapy well with a useful but suboptimal response, combination therapy should be considered, particularly if there is a high seizure density and demonstrable underlying pathology, such as mesial temporal sclerosis or cortical dysplasia (Table 2 ). Several duotherapy combinations should be tested sequentially before adding a third drug. Higher numbers of AEDs should be avoided if possible as it is highly unlikely that this strategy will produce useful seizure reduction without side effects. 97 A personalized treatment plan should be formulated once a patient fulfils the criterion for drug-resistant epilepsy to limit as far as possible cognitive deterioration and psychosocial dysfunction, while taking into consideration seizure type(s) and syndrome classification. 98 This has recently been defined by an International
League Against Epilepsy task force as ''failure of an adequate trial of two tolerated, appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom''. 99 The development of this definition encourages a more aggressive approach toward earlier combination therapy and more rapid access to non-pharmacological treatment options, such as vagal nerve stimulation or epilepsy surgery. 100 Special attention should be paid to drug load to avoid side-effects and optimise the potential for complete seizure control. 101 It would also be worthwhile raising the possibility at this early stage that seizure freedom may not be attainable, paving the way for a later palliative strategy if this proves to be necessary.
All patients with refractory epilepsy should be informed of the risk of sudden unexpected death in epilepsy and appropriate precautions taken.
102
Even with the contribution from experimental combination studies, the issue of rational polypharmacy for epilepsy remains largely unresolved. This is, to some extent, due to uncertainty about the definition. If it is the application of common sense, then we should combine drugs with different, perhaps multiple, mechanisms of action in order to cover more pharmacological bases. If it is to be evidence-based, then robust evidence does not exist in support of the above strategy with the exception of combining sodium valproate with lamotrigine. Whatever strategy we use is confounded by our incomplete understanding of how AEDs work, not to mention our lack of knowledge about the neurobiologies underpinning most epilepsies. These deficiencies arguably limit our ability to use single drugs in a rational manner, far less in combinations. However, on the basis of current experimental and clinical evidence, it would appear that combining AEDs with similar mechanisms of action is counter-intuitive and counter-productive. At present, however, this principle can only be reasonably applied to selective sodium channel blockers and not other mechanistic classes of AEDs.
Conclusion
After being viewed as a last resort for many years, the role of combination therapy as an acceptable treatment strategy for epilepsy is undergoing re-evaluation. This is a result of the growing appreciation that a substantial proportion of patients will not respond optimally to monotherapy, coupled with the availability of a wide range of modern AEDs, some of which are better tolerated and less prone to complex pharmacokinetic drug interactions than their older counterparts. Convincing evidence to guide clinicians on when and how to combine AEDs is still lacking, and current practice recommendations remain empirical. Well designed studies exploring the ever expanding possibilities of AED combinations would address these practical questions so that effective therapy could be offered to many more patients in a pharmacologically targeted fashion. A mechanistic approach to the pharmacological management of each epilepsy syndrome has the potential to optimise the chance of perfect seizure control and help more people achieve safer and more fulfilled lives. A palliative strategy will be necessary for the many patients with truly refractory epilepsy.
